Core Viewpoint - InnoCare Pharma's next-generation TRK inhibitor zurletrectinib has received priority review from the CDE for treating pediatric patients with solid tumors harboring NTRK gene fusions, highlighting the company's commitment to addressing unmet medical needs in oncology [1][2]. Group 1: Drug Approval and Clinical Trials - Zurletrectinib has been granted priority review by the CDE for pediatric patients aged 2 to 12 with solid tumors harboring NTRK gene fusions [1]. - The drug was previously approved in December 2025 for adult and adolescent patients (aged 12 years and older) with similar conditions, demonstrating an objective response rate (ORR) of 89.1% and a disease control rate (DCR) of 96.4% in clinical trials [3]. - Data from a Phase I/II clinical trial presented in October 2025 indicated that zurletrectinib has a well-tolerated safety profile and promising antitumor activity in pediatric/adolescent patients with NTRK/ROS1-altered solid tumors [4]. Group 2: Market Need and Potential - NTRK fusion genes are prevalent in various tumors, with some rare types showing an incidence exceeding 90%, indicating a significant clinical need for effective treatments [5]. - Approximately 6,500 new cases of NTRK fusion-positive solid tumors are diagnosed annually in China, underscoring the demand for innovative therapies in this area [5]. Group 3: Company Overview - InnoCare is a biopharmaceutical company focused on developing first-in-class and best-in-class drugs for cancer and autoimmune diseases, with operations in multiple locations including Beijing, Nanjing, Shanghai, Guangzhou, Hong Kong, and the United States [6].